Marginal Zone Lymphoma Pipeline Report – Insights Into the Emerging Therapies, Clinical Trials, and Treatment Outlook | Companies – NantKwest, AbbVie, ImmunityBio, ArQule, Bayer, BeiGene, and Others

Delveinsight Business Research LLP
“Marginal Zone Lymphoma Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.

The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Marginal Zone Lymphoma Pipeline Analysis

The report provides insights into: 

The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Marginal Zone Lymphoma Treatment.

Marginal Zone Lymphoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Marginal Zone Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Download Sample Pages @

Marginal Zone Lymphoma Therapeutics Landscape

The Marginal Zone Lymphoma Therapeutics Market is categorized into three types based on the line of therapies, i.e., first-line, second-line, and third-line of therapiesTreatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, stage, and location of the disease. 

Several pharmaceutical key players have taken the initiative to meet the unmet needs of the present situation of the Marginal Zone Lymphoma market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. The launch of emerging products will fuel the Marginal Zone Lymphoma market growth.

Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:






Bristol-Myers Squibb

Celgene Corporation

Cellectar Biosciences

Eli Lilly

Gilead Sciences

InnoCare Pharma

Innovent Biologics

Janssen Biotech

Loxo Oncology

MEI Pharma



Nordic Nanovector

Roche Pharma

TG Therapeutics

TriSalus Life Sciences

Verastem/Secura Bio

And many others


Marginal Zone Lymphoma Therapies covered in the report include:

Revlimid (lenalidomide) in combination with rituximab

Imbruvica (ibrutinib)

Umbralisib (TGR-1202)

Aliqopa (Copanlisib)



Yescarta (axicabtagene ciloleucel)

Keytruda (Pembrolizumab)

CLR 131


Nivolumab (Oppdivo)

Calquence (acalabrutinib)

Betalutin (177Lu-satetraxetan-lilotomab) 

Navitoclax (ABT-263)

Orelabrutinib (ICP-022)


ARQ 531







And many more.

Request for Sample Pages @

Table of Content

1. Report Introduction

2. Marginal Zone Lymphoma 

3. Marginal Zone Lymphoma Current Treatment Patterns

4. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Marginal Zone Lymphoma Late Stage Products (Phase-III)

7. Marginal Zone Lymphoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Marginal Zone Lymphoma Discontinued Products

13. Marginal Zone Lymphoma Product Profiles

14. Marginal Zone Lymphoma Key Companies

15. Marginal Zone Lymphoma Key Products

16. Dormant and Discontinued Products

17. Marginal Zone Lymphoma Unmet Needs

18. Marginal Zone Lymphoma Future Perspectives

19. Marginal Zone Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report:

Other Latest Reports By DelveInsight

Follicular Lymphoma Market

DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States